Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting

Phase 3positiveTegoprazanPositive

AI Analysis

Summary

Sebela Pharmaceuticals will present positive Phase 3 data for Tegoprazan in non-erosive reflux disease, demonstrating clinical improvement in both heartburn and regurgitation symptoms at the ACG 2026 meeting. The drug is reported as the first and only P-CAB to show such efficacy in both hallmark NERD symptoms in a prospective U.S. Phase 3 trial.

Clinical Trial Data

Phase

Phase 3

Primary Endpoint

Met

Outcome Details

Tegoprazan demonstrated clinical improvement in both heartburn and regurgitation in a randomized, double-blind, placebo-controlled Phase 3 trial

Importance:7/10

Sentiment:

0.80

Phase 3positive dataGERDP-CABconference presentation

Related Companies

$AHR $TRAX

Read the original article

Published by PR Newswire Pharma on October 11, 2026 5:00 PM

Read Original